Fiduciary Alliance LLC Buys 3,324 Shares of Abbott Laboratories (NYSE:ABT)

Fiduciary Alliance LLC raised its stake in Abbott Laboratories (NYSE:ABT) by 83.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,304 shares of the healthcare product maker’s stock after acquiring an additional 3,324 shares during the period. Fiduciary Alliance LLC’s holdings in Abbott Laboratories were worth $833,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Scarborough Advisors LLC bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $84,000. Richardson Financial Services Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $29,000. SageView Advisory Group LLC grew its holdings in shares of Abbott Laboratories by 14.2% during the fourth quarter. SageView Advisory Group LLC now owns 13,005 shares of the healthcare product maker’s stock worth $1,476,000 after purchasing an additional 1,619 shares during the last quarter. Nomura Holdings Inc. grew its holdings in shares of Abbott Laboratories by 1,566.0% during the fourth quarter. Nomura Holdings Inc. now owns 34,986 shares of the healthcare product maker’s stock worth $3,851,000 after purchasing an additional 32,886 shares during the last quarter. Finally, Trust Co. of Toledo NA OH grew its holdings in shares of Abbott Laboratories by 0.9% during the first quarter. Trust Co. of Toledo NA OH now owns 72,196 shares of the healthcare product maker’s stock worth $8,206,000 after purchasing an additional 630 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Up 1.0 %

NYSE ABT opened at $117.25 on Tuesday. The stock’s 50-day moving average is $113.31 and its 200-day moving average is $108.32. Abbott Laboratories has a one year low of $90.87 and a one year high of $121.64. The firm has a market cap of $203.97 billion, a P/E ratio of 36.53, a P/E/G ratio of 2.74 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.68 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The business had revenue of $10.38 billion for the quarter, compared to analyst estimates of $10.37 billion. During the same quarter last year, the firm earned $1.08 EPS. Abbott Laboratories’s revenue for the quarter was up 4.0% compared to the same quarter last year. Sell-side analysts anticipate that Abbott Laboratories will post 4.66 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date of this dividend is Tuesday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 68.54%.

Analyst Ratings Changes

Several research firms recently issued reports on ABT. Jefferies Financial Group reiterated a “hold” rating and issued a $120.00 price target on shares of Abbott Laboratories in a report on Thursday, September 26th. Barclays raised their price target on Abbott Laboratories from $140.00 to $143.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Citigroup raised their price target on Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Royal Bank of Canada increased their target price on Abbott Laboratories from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Evercore ISI increased their target price on Abbott Laboratories from $120.00 to $124.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $125.54.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the completion of the transaction, the chief executive officer now directly owns 220,059 shares in the company, valued at $25,617,068.19. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.10% of the stock is owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.